Related Experiment Video
Updated: May 2, 2026
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
1.4K
Coagulation tests show significant differences in patients with breast cancer
Faruk Tas1, Leyla Kilic, Derya Duranyildiz
1Institute of Oncology, University of Istanbul, Capa, 34390, Istanbul, Turkey, faruktas2002@yahoo.com.
Summary
Blood coagulation tests reveal significant differences in breast cancer patients compared to controls. Elevated D-dimer levels correlate with metastatic disease and older age in breast cancer.
Area of Science:
- Oncology
- Hematology
- Biochemistry
Background:
- Coagulation and fibrinolysis are activated in cancer patients, linked to tumor stroma and metastasis.
- Understanding these systems in breast cancer is crucial for prognosis and treatment.
Purpose of the Study:
- To investigate the correlation between blood coagulation assays and clinicopathologic factors in breast cancer patients.
- To identify potential biomarkers for breast cancer progression and metastasis.
Main Methods:
- A cohort of 123 treatment-naïve female breast cancer patients was studied.
- Pretreatment coagulation tests (PT, APTT, PTA, INR, D-dimer, fibrinogen, platelet count) were evaluated.
- Coagulation parameters were analyzed against clinicopathologic factors like age, tumor stage, and metastasis.
Main Results:
- Coagulation tests (except PT) showed significant differences between breast cancer patients and controls.
- Higher D-dimer levels were associated with older age (>50 years) and metastatic breast cancer.
- Advanced tumor stage (T3/T4) correlated with higher INR and lower PTA.
Conclusions:
- Blood coagulation assays demonstrate significant alterations in breast cancer patients.
- Specific coagulation markers may serve as indicators for disease progression and metastatic potential in breast cancer.
